| General Information of Drug Metabolite (DM) (ID: DM019338) |
| DM Name |
KRP-297 Metabolite M25
|
| Structure |
|
|
3D MOL is unavailable
|
2D MOL is unavailable
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Tryptase gamma (TMT)
|
DMEN821
|
| Unclear - Unclear |
KRP-297
|
[1] |
|
|
|
|
|
|
|
| DME(s) Metabolizing This DM |
| DME Name |
DME ID |
Product |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
KRP-297
|
[1] |
|
Dimethylaniline oxidase 3 (FMO3)
|
DME0039
|
| Unclear - Unclear |
KRP-297
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| KRP-297 |
DR2971
|
Discontinued in Phase 2 |
Hypertriglyceridaemia |
|
|
| References |
| 1 |
Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
